Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.50 USD

86.50
3,439,683

-1.09 (-1.24%)

Updated Nov 15, 2024 01:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands

DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.

Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics

Boston Scientific, ResMed, Lantheus and Haemonetics are part of the Zacks Industry Outlook article.

Veeva's (VEEV) Vault EDC to Boost Vita Global's Data Management

Veeva's (VEEV) Vault EDC is likely to improve Vita Global's clinical data management processes.

McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.

Patterson Companies (PDCO) Q4 Earnings Miss, Sales Rise Y/Y

Patterson Companies' (PDCO) fourth-quarter fiscal 2024 results reflect a year-over-year improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales improve.

Venus Concept's (VERO) Latest Supply Deal to Aid its Business

Venus Concept (VERO) announces an exclusive strategic supply arrangement with Skin Laundry Holdings, Inc.

BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold

BrainsWay's (BWAY) latest exclusive multi-year distribution agreement is likely to provide improved patient care in Canada.

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Boston Scientific (BSX) to Buy Silk Road, Boost Cardiology

This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy From a Recovering Industry

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.

Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

The latest trading day saw Boston Scientific (BSX) settling at $76.31, representing a +0.16% change from its previous close.

Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Merit Medical (MMSI) Recalls Syringes Made by Jiangsu Shenli

Merit Medical (MMSI) recalls certain products containing syringes made by a Chinese manufacturer, Jiangsu Shenli.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

GE HealthCare's (GEHC) New Tie-Up to Boost Patient Care in Mexico

GE HealthCare's (GEHC) latest agreement is likely to standardize care protocols and improve the quality of CT, MR and ultrasound examinations.

Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy

Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.

Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure

Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.

3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

HAE vs. BSX: Which Stock Should Value Investors Buy Now?

HAE vs. BSX: Which Stock Is the Better Value Option?

Patterson Companies' (PDCO) Launch to Boost Insurance Workflow

Patterson Companies' (PDCO) latest offering is likely to offer customers additional options for their electronic insurance processing and patient billing statement workflow.

HealthEquity (HQY) Gains 25.3% YTD: What's Driving the Rally?

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA

Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.